140 related articles for article (PubMed ID: 20126848)
1. Prostate cancer and acromegaly.
Corrêa LL; Lima GA; Paiva HB; Silva CM; Cavallieri SA; Miranda LC; Gadelha MR
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):963-8. PubMed ID: 20126848
[TBL] [Abstract][Full Text] [Related]
2. Prostatic hyperplasia: an unknown feature of acromegaly.
Colao A; Marzullo P; Ferone D; Spiezia S; Cerbone G; Marinò V; Di Sarno A; Merola B; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):775-9. PubMed ID: 9506725
[TBL] [Abstract][Full Text] [Related]
3. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects.
Colao A; Marzullo P; Spiezia S; Ferone D; Giaccio A; Cerbone G; Pivonello R; Di Somma C; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1986-91. PubMed ID: 10372698
[TBL] [Abstract][Full Text] [Related]
4. Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5α-reductase inhibitors: A 15-year longitudinal case report.
Chen YC; Chen HW; Chen MT; Huang CH; Li CC; Juan YS; Ke HL
Low Urin Tract Symptoms; 2019 Apr; 11(2):O218-O220. PubMed ID: 29405593
[TBL] [Abstract][Full Text] [Related]
5. Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients.
Colao A; Marzullo P; Spiezia S; Giaccio A; Ferone D; Cerbone G; Di Sarno A; Lombardi G
J Clin Endocrinol Metab; 2000 Oct; 85(10):3754-61. PubMed ID: 11061535
[TBL] [Abstract][Full Text] [Related]
6. Prostatic disorders in acromegalic patients experience of a Brazilian center.
Corrêa LL; Balarini Lima GA; Cavallieri SA; Miranda LC; Gadelha MR
Int Braz J Urol; 2013; 39(3):393-401. PubMed ID: 23849571
[TBL] [Abstract][Full Text] [Related]
7. Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients.
Colao A; Spiezia S; Di Somma C; Marzullo P; Cerbone G; Pivonello R; Faggiano A; Lombardi G
Eur J Endocrinol; 2000 Jul; 143(1):61-9. PubMed ID: 10870032
[TBL] [Abstract][Full Text] [Related]
8. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone and prostate cancer: guilty by association?
Grimberg A; Cohen P
J Endocrinol Invest; 1999; 22(5 Suppl):64-73. PubMed ID: 10442574
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
11. IGFs and human cancer: implications regarding the risk of growth hormone therapy.
Shim M; Cohen P
Horm Res; 1999; 51 Suppl 3():42-51. PubMed ID: 10592443
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of differentiated thyroid carcinoma in acromegaly.
Tita P; Ambrosio MR; Scollo C; Carta A; Gangemi P; Bondanelli M; Vigneri R; degli Uberti EC; Pezzino V
Clin Endocrinol (Oxf); 2005 Aug; 63(2):161-7. PubMed ID: 16060909
[TBL] [Abstract][Full Text] [Related]
13. Cancers associated with acromegaly.
Jenkins PJ
Neuroendocrinology; 2006; 83(3-4):218-23. PubMed ID: 17047386
[TBL] [Abstract][Full Text] [Related]
14. Acromegaly: re-thinking the cancer risk.
Loeper S; Ezzat S
Rev Endocr Metab Disord; 2008 Mar; 9(1):41-58. PubMed ID: 18157698
[TBL] [Abstract][Full Text] [Related]
15. Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly.
Ronchi CL; Coletti F; Fesce E; Montefusco L; Ogliari C; Verrua E; Epaminonda P; Ferrante E; Malchiodi E; Morelli V; Beck-Peccoz P; Arosio M
J Endocrinol Invest; 2009 Jun; 32(6):495-500. PubMed ID: 19494714
[TBL] [Abstract][Full Text] [Related]
16. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
17. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
18. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
19. IGF-I, insulin and prostate cancer.
Lima GA; Corrêa LL; Gabrich R; Miranda LC; Gadelha MR
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):969-75. PubMed ID: 20126849
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
